FDAnews’ staff has culled through questions submitted to OGCP about human test subjects and curated more than 100 of the most relevant responses for you — segmented by category.
Some of these may be questions you’ve asked yourself and others you may not have even thought of. But all of them get straight to the heart of your role as a clinical trial professional — how to conduct safe, effective, compliant trials that can win FDA approval.
This collection sheds light on some of the most difficult and important topics in clinical trial research, including:
Exact wording of informed consent forms (ICF)
Witnessing signature of ICFs
Procedures for re-consenting subjects
Potential HIPAA violations
Collecting information on pregnant subjects
Communicating with unresponsive subjects
This book also includes copies of documents and other resources most often recommended by OGCP:
Investigator Responsibilities — Protecting the Rights, Safety, and Welfare of Study Subjects.
Questions and Answers on Informed Consent Elements, 21 CFR § 50.25(c) (Small Entity Compliance Guide)
Screening Tests Prior to Study Enrollment
ICH E6 — Good Clinical Practice: Consolidated Guidance
Informed Consent Information Sheet
Data Retention When Subjects Withdraw from FDA-regulated Clinical Trials
Get answers to human subject questions clinical research professionals ask of OGCP.
Order Your Copy Today
PDF Edition — $397
Who Will Benefit
Manufacturers’ R&D departments
Hospitals’/medical centers’ clinical trial heads
Save money with a license agreement allowing significant numbers of users access to an electronic version of this book. For multi-user access to multiple titles, FDAnews offers the FDAnews Online Library — a personalized collection of FDAnews publications that is fully searchable. Contact Customer Service for a quote or more information.
Not satisfied with your publication? For the PDF version, you must notify FDAnews within 24 hours of receipt of purchase and we will refund 100 percent of your purchase price.